Biomarkers for tau pathology

Michael Schöll1,2,5,*, Anne Maas3,4,*, Niklas Mattsson2,3, Nicholas J. Ashton2,4, Kaj Blennow5, Henrik Zetterberg6,7, William Jagust9,10

1 Wallenberg Centre for Molecular and Translational Medicine and the Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden
2 Clinical Memory Research Unit, Lund University, Malmö, Sweden
3 Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
4 German Center for Neurodegenerative Diseases, Magdeburg, Germany
5 Helen Wills Neuroscience Institute, University of California, Berkeley, USA
6 Department of Neurology, Skåne University Hospital, Lund, Sweden
7 King’s College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK
8 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
9 UK Dementia Research Institute at UCL, London, UK
10 Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, USA

A B S T R A C T

The aggregation of fibrils of hyperphosphorylated and C-terminally truncated microtubule-associated tau protein characterizes 80% of all dementia disorders, the most common neurodegenerative disorders. These so-called tauopathies are hitherto not curable and their diagnosis, especially at early disease stages, has traditionally proven difficult. A keystone in the diagnosis of tauopathies was the development of methods to assess levels of tau protein in vivo in cerebrospinal fluid, which has significantly improved our knowledge about these conditions. Tau proteins have also been measured in blood, but the importance of tau-related changes in blood is still unclear. The recent addition of positron emission tomography ligands to visualize, map and quantify tau pathology has further contributed with information about the temporal and spatial characteristics of tau accumulation in the living brain. Together, the measurement of tau with fluid biomarkers and positron emission tomography constitutes the basis for a highly active field of research.

This review describes the current state of biomarkers for tau biomarkers derived from neuroimaging and from the analysis of bodily fluids and their roles in the detection, diagnosis and prognosis of tau-associated neurodegenerative disorders, as well as their associations with neuropathological findings, and aims to provide a perspective on how these biomarkers might be employed prospectively in research and clinical settings.

1. Introduction

Proteinopathies are diseases where pathogenic post-translational modifications (PTMs), such as excess phosphorylation, misfolding, and aggregation of proteins are unregulated and misfolded proteins accumulate, harming cells and their environment (Fontaine et al., 2015; Ren et al., 2014; Walker and LeVine 3rd, 2012). Disorders associated with the accumulation of the microtubule-associated protein tau are thus termed tauopathies. Tau, among other physiological roles, stabilizes microtubules and maintains synaptic integrity and function. Under pathological conditions, however, its amyloidic ("starch-like") nature (Sipe et al., 2016) results in self-aggregation into aberrant fibrillar β-sheet structures, which accumulate intracellularly and cause synaptic dysfunction and degeneration (Iqbal et al., 2016). Six isoforms of tau are expressed in the human brain, resulting from alternate splicing of the MAPT gene on chromosome 17 and differing in the number of amino terminal insertions (0/1/2N) and the number of microtubule-binding domain repeats, either three (3R) or four (4R) (Goedert et al., 1989). The neuropathology of different tauopathies exhibits varying isoform composition of the different intracellular tau inclusions as well as distinct neuron anatomical distribution and relative amounts of tau inclusions. Common tauopathies include certain variants of frontotemporal lobe dementia (FTD) - frontotemporal lobar degeneration-tau (FTLD-tau) (Mackenzie and Neumann, 2016) - such as autosomal-dominant FTLD-17, where mutations in MAPT cause mixed 3R/4R tau inclusions whose grey and white matter distribution can overlap with sporadic tauopathies; Pick's disease (PiD), characterized by so-called Pick bodies, round inclusions formed almost exclusively by 3R tau aggregating along spatial phases in neocortical layers II-IV and certain cell populations of the hippocampus (Irwin et al., 2016); progressive...
nuclear palsy (PSP), characterized by predominant 4R tau inclusions mainly in specific nuclei of the basal ganglia, diencephalon, brainstem and cerebellum, with limited involvement of the neocortex (Dickson et al., 2010); cortico-basal degeneration (CBD) with 4R-dominant tau pathology grossly overlapping with PSP with a tendency to greater involvement of the cerebral cortex and especially white matter (Dickson et al., 2011; Ouchi et al., 2014); and Alzheimer’s disease (AD), which accounts for the vast majority of tauopathies and is characterized by mixed 3R/4R mixed tau pathology accumulating in distinct spatial and temporal stages (Braak stages, see below) (Braak and Braak, 1991; Braak et al., 2011).

In 1906, Alois Alzheimer presented what he found in the brain of the alleged first patient to be diagnosed with AD. What he described as “Eigentümliche Veränderungen der Hirnrinde” (“Peculiar changes of the brain’s cortex”) at a conference in Tübingen, Germany, was likely the first description of AD-typical neurofibrillary tangle pathology, which together with plaques, composed of fibrillar β-amyloid (Aβ) protein, constitute the macro pathological hallmarks of AD. It would take another 80 years until hyperphosphorylated tau was identified as a core component of AD-related paired helical filaments (PHF), the main components of neurofibrillary tangles (NFT) (Grundke-Iqbal et al., 1986a; Grundke-Iqbal et al., 1986b; Ihara et al., 1986; Kosik et al., 1986; Wood et al., 1986). Another decade later, in vivo assessment of tau became possible through the development of assays for the detection of total (T-tau) and phosphorylated tau (P-tau) in cerebrospinal fluid (CSF) (Blinnlow et al., 1995). Five years ago, positron emission tomography (PET) ligands binding to tau with high affinity were introduced, enabling the visualization, mapping, and quantification of tau in the living brain (Chien et al., 2013).

Ongoing treatment trials targeting tau pathology now call for reliable and quantifiable tau biomarkers for the early identification of eligible study participants and the in vivo quantification of potential treatment effects (Cummings et al., 2018; Khanna et al., 2016). Furthermore, the National Institute on Aging and Alzheimer Association (NIA-AA) research criteria in the diagnosis of AD (Jack Jr. et al., 2018a) have implemented the use of tau biomarkers derived from PET and CSF, however, it remains unclear how the different biomarkers may be optimally operationalized.

Here, we summarize the current state of fluid- and imaging-derived markers for tau pathology.

2. Fluid biomarkers of tau

2.1. Tau in CSF

Over three decades ago, the finding that P-tau was the major component of tangles (Grundke-Iqbal et al., 1986b) made tau proteins in CSF prime candidates for quantitative immunoassays. Today, both CSF T-tau and P-tau assays (along with low Aβ42) are central to the Internal Working Group (IWG) (Dubois et al., 2014) and the NIA-AA (Jack Jr. et al., 2018a) research criteria in the diagnosis of AD. In AD, neurons release more tau proteins to the extracellular space, which is reflected in CSF from patients as increased concentrations of both T-tau, measured using antibodies against mid-domain tau epitopes that are not phosphorylated, and P-tau that is measured using antibody combinations that specifically recognize mid-domain P-tau epitopes (Olsson et al., 2016). These biomarker changes correlate with each other, however, this association is most pronounced in AD and less pronounced for isolated increases in T-tau (Skillback et al., 2015). CSF T-tau and P-tau correlate with AD-type neurodegeneration and tangle pathology in autopsy and biopsy studies (Buerger et al., 2006; Seppala et al., 2012; Tapiola et al., 2009), but the correlations are modest, and not reported in all studies (Engelborghs et al., 2007). This appears to be different from correlation studies between tau PET imaging and CSF tau biomarkers (see below), and immediately suggest differences in how these different biomarker modalities reflect the underlying processes in AD.

CSF T-tau has been postulated to reflect the severity of acute injury and/or on-going neurodegeneration (Blinnlow and Hampel, 2003). CSF T-tau is likely increased very early in the disease process since increased levels can be seen already in Aβ-positive cognitively unimpaired individuals (CU) (while other markers of injury, including neurogranin and neurofilament light protein were not increased until the prodromal stage in the same cohort (Mattsson et al., 2016a)). However, the increase in CSF T-tau is not specific to AD, since CSF T-tau levels are the highest in conditions with the most severe neurodegeneration, including Creutzfeldt-Jakob disease, which has been shown to be 10-times higher in T-tau concentrations than dementia (Skillback et al., 2014). Following acute brain injury, a rapid spike in CSF T-tau is observed and maintained for a number of weeks before slowly declining to normal levels (Hesse et al., 2001; Zetterberg et al., 2006). In AD, higher T-tau values predict a more rapid cognitive decline (Buchhave et al., 2012; Wallin et al., 2010), and relate to more rapid hippocampal atrophy and reductions in FDG-PET binding (Mattsson et al., 2016a; Chiaravalloti et al., 2018), which supports the idea that T-tau levels are related to the intensity of neurodegeneration.

Several validated commercially available immunoassays targeting threonine 181 (P-tau181) consistently demonstrate an increase in AD. However, other mid-domain P-tau residues (threonine 231, serine 199 and 231) and C-terminal residues (Serine 396 and 404) are also increased in AD (Hu et al., 2002; Ishiguro et al., 1999; Kohnken et al., 2000). A limited number of studies seem to demonstrate co-linearity but specificity in P-tau181, 199 and 231 to distinguishing AD from other neurodegenerative disorder and aged healthy controls (Hampel et al., 2004).

A major outstanding research question is why other tauopathies, including some forms of FTD and associated disorders like PSP, do not show increased P-tau concentration in the CSF, at least not as robustly as in AD (Zetterberg, 2017). It is possible that disease-specific phosphorylation of tau occurs in these disorders, or that tau is processed or truncated in a way that is not recognized by the available assays. Another potential explanation for why increased CSF T-tau and P-tau are specific to AD is that this particular pathological change is simply more extensive and severe in AD than in other tauopathies. However, this seems contradicted by the fact that some non-AD tauopathy patients, most notably PSP patients, even have decreased CSF P-tau levels compared to control populations (Hall et al., 2012; Meeter et al., 2018; Wagshal et al., 2015).

Yet another possibility is that CSF T-tau and P-tau increase reflects a neuronal response to Aβ pathology, which precedes neurodegeneration and tangle pathology, as suggested by mouse model studies (Maia et al., 2013) and tau kinetics studies in humans (Sato et al., 2018). This is in agreement with the poor correlation between CSF T-tau and P-tau with [18F]Flortaucipir (FTP) imaging in early stages of AD, as discussed further below.

It is known that the major proportion of tau is cleaved to N-terminally truncated or N-terminal to mid domain fragments before being secreted to the CSF, while C-terminal fragments are much less abundant (Barhelemy et al., 2016; Meredith Jr. et al., 2013). Recent studies have identified tau species cleaved by asparagine endopeptidase (AEP), that generate tau fragments ending at amino acid 368 (based on tau 2 N/4R tau numbering), which are up-regulated in aging and AD, and which have an increased tendency for aggregation into tangles (Zhang et al., 2014). Future research to evaluate if tau368 or other C-terminally extended tau fragments measured in CSF may serve as biomarkers for tau pathology is warranted.

2.2. Tau in plasma

Both imaging (see below) and CSF biomarkers work well to identify AD pathophysiology. Nonetheless, PET imaging is costly and access is restricted to specialized centers. Gradually, CSF sampling for analysis of
AD biomarkers is becoming increasingly used in clinical practice for management of neurodegenerative diseases, yet there remains a level of perceived invasiveness or complexity attached to a lumbar puncture in many countries. The accessibility and ease of blood sampling provides significant practical advantages for measuring AD biomarkers, for both clinical assessment or screening and repeated sampling in therapeutic trials.

Blood communicates with the brain across the blood-brain barrier, via lymph vessels and through the glymphatic system (Plog and Nedergaard, 2018; Zetterberg and Blennow, 2018). Despite this, it has proven difficult to establish the core CSF biomarkers for AD pathology in blood. Firstly, due to its continuous and uninhibited exchange with the brain, biomarkers in CSF will be considerably higher in concentration than biomarkers in blood. Furthermore, once entering the bloodstream, brain-derived proteins will compete in a complex matrix of highly abundant plasma proteins (e.g. albumin, IgG, transferrin, haptoglobin, and fibrinogen) that span > 10 orders of magnitude. Secondly, a brain-derived biomarker may undergo protease degradation, metabolized by the liver and cleared by the kidneys or simply have substantial expression by peripheral tissues. Lastly, analytical factors such as interference from heterophilic antibodies or variations in blood collection, processing and storage can have a major influence on an individual result. All these factors will introduce a high degree of variability that is unrelated to the disease pathogenesis and will be difficult to normalize.

In the advent of emerging ultrasensitive techniques that resolve confounding matrix effects, the femtomolar detection of proteins in blood has been demonstrated (Rissin et al., 2010). Indeed, increased plasma levels of T-tau in AD compared to CU and/or MCI (mild cognitive impairment) have been exhibited by immunomagnetic reduction (IMR) (Tzen et al., 2014) and Single molecule array (Simoa) (Zetterberg et al., 2013). More recently, in the ADNI and BioFINDER cohorts, this finding was confirmed but with large overlaps between the clinical groups, which almost certainly concludes that plasma T-tau is not diagnostically useful in a cross-sectional manner (Mattsson et al., 2016b). Conversely, baseline plasma T-tau might be useful in predicting future cognitive decline (Mattsson et al., 2016b; Mielke et al., 2017), atrophy and hypermetabolism (Mattsson et al., 2016b). Likewise, in cardiac arrest, with much greater acute neuronal injury than AD, baseline plasma T-tau may be used for prognosis of patients with poor neurological outcome (Mattsson et al., 2017c). Plasma T-tau, however, correlates poorly with CSF T-tau (Mattsson et al., 2016b; Zetterberg et al., 2013), which might have several explanations, e.g. rapid peripheral degradation of tau or that blood tau levels are confounded by expression of tau in peripheral tissues. As with CSF, assays directed towards truncated fragments of tau in plasma may yield greater disease specificity.

At this time there is no validated assay for P-tau in blood. Nonetheless, recent pilot data have reported encouraging findings. The Simoa and Meso Scale Discovery (MSD) platforms have both been utilized to demonstrate an increase of P-tau181 concentration in AD patients compared to healthy controls (Mielke et al., 2018; Tatebe et al., 2017). Importantly, however, both these studies reported weak but significant correlations with either CSF P-tau181 (Tatebe et al., 2017) or FTP (Mielke et al., 2018). Intriguingly, the stated concentrations of P-tau181 between the two methods differ substantially (Simoa assay reported a mean concentration of 0.171 pg/mL in AD patients versus 12 pg/mL on the MSD platform). In another recent paper, plasma P-tau231 was measured using a fiber optics technique in which antibody-based detection was combined with rolling circle amplification (Rubenstein et al., 2017). Increased concentrations of plasma P-tau231 in patients with traumatic brain injury (TBI) were observed but as of yet no data has been reported in AD. This promising data, albeit preliminary, on P-tau makes it one of the most anticipated areas of AD biomarker research alongside plasma Aβ42/α42 (Ashton et al., 2018a, 2018b) and neurofilament light chain (Mattsson et al., 2017a).

Other areas of ongoing investigation for peripheral tau include, but are not limited to, exosomes and saliva. Increases in T-tau and P-tau within neuronal-derived exosomes in plasma have been a developing area of research (Fiandaca et al., 2015; Winston et al., 2016). As it stands, further validation of these results and methodologies are needed. It has previously been shown that T-tau is readily measurable in saliva (Ashton et al., 2018a). While concentrations are noticeably higher than plasma, no statistically significant difference across diagnostic groups was observed. Preliminary proteomic data suggests that certain P-tau fragments derived in saliva may be of importance in clinical AD, however this is yet to be determined using a robust platform in large sample sizes.
3. Tau positron emission tomography (PET)

Given the molecular diversity of tauopathies, it cannot be assumed that one PET ligand or even one class of chemically similar PET ligands will be useful in the research of all disorders. Several companies and academic groups have developed and are continuously developing ligands presumably binding to tau (please refer to Fig. 1 for the chemical structures of current alleged tau PET ligands). Based on the recently published cryo-EM structure for the tau fibril (Fitzpatrick et al., 2017), four binding sites have been suggested for current PET ligands, and different candidates show differential preference for each of these sites (Murugan et al., 2018).

3.1. First-generation tau PET ligands

The first PET ligand used to visualize the molecular underpinnings of AD was [18F]FDDNP (Shohji-Jadid et al., 2002), which binds to both Aβ fibrils and tau NFT. Due to its relative nonspecificity for one or the other it has largely been replaced by tau or Aβ-specific ligands.

One of the earliest agents developed specifically for tau imaging was the carbon-11 labelled PBB3, a pyrinated phenyl- and pyridinyl-buta-dienyl-benzothiazole with a 50-fold higher affinity to tau over Aβ deposits (Maruyama et al., 2013). [11C]PBB3 was initially found to exhibit affinity to tau in AD, PSP and CBD tissue samples (Ono et al., 2017b), however its utility was hampered by high white matter uptake, low target to white matter ratio on autoradiography in AD tissue, its fast metabolism in vivo (< 8% remaining 3 min after injection) (Hashimoto et al., 2014), photo-isomerization upon exposure to fluorescent light, and a dominant brain-penetrant metabolite that complicated quantification of ligand uptake (Hashimoto et al., 2015). Finally, carbon-11 labelling with its short half-life (~20 min) limits potential use of any PET ligand as compared to fluorine-18 labelling (half-life ~110 min). To address these issues, the fluorine-18 analogues AM-PBB3 and PM-PBB3 were developed (Ono et al., 2017a; Shimada et al., 2017a) but limited data have been published to date.

A series of compounds have been developed at Tohoku University, Japan, the most widely used being the arylquinoline derivatives [18F]THK5117 (Okamura et al., 2013) and [18F]THK5351. Of these two, [18F]THK5351 demonstrated favorable imaging characteristics, generally demonstrating higher grey matter and lower white matter uptake but lower lipophilicity (Bettahsera et al., 2017a). The S-enantiomer form of [18F]THK5117, [18F]THK5351, has also been assessed in vivo (Chiotis et al., 2016; Jonasson et al., 2016). However, high off-target binding of [18F]THK5351 was observed especially in the thalamus, and blocking studies with the monoamine oxidase B (MAO-B) inhibitor seleagine showed dramatic reduction in thalamic [18F]THK5351 uptake (Ng et al., 2017a). Cortical uptake was also reduced significantly, indicating that this off-target binding also affected what had been previously assumed to be tau specific uptake in in vivo studies (see also below).

The radioligand [18F]Flortaucipir (FTP, previously AV1451 or T807), a benzimidazole pyrimidine derivative, is the by far most widely studied tau PET tracer to date. It has been shown to bind with high affinity (25–27 fold larger than to Aβ) to 3R and 4R tau isoforms in PHF of AD patients (Chien et al., 2013; Lowe et al., 2016; Marquie et al., 2015). Smith and colleagues furthermore showed that in vivo FTP-binding and post-mortem PHF load were highly correlated in one subject with a MAPT R406W mutation causing AD-like tau pathology (Smith et al., 2016). However, large inter- and intra-individual differences were observed in a recent study in post mortem tissue from several neurodegenerative disorders (Wren et al., 2018), calling for further investigation of the binding characteristics. Nonetheless, on a group level, FTP demonstrated clinical usefulness when its discriminative accuracy between AD dementia and non-AD neurodegenerative disorders was examined in a large multisite study, yielding 89.9% (95% CI, 84.6%–93.9%) sensitivity and 90.6% (95% CI, 86.3%–93.9%) specificity or 96.8% (95% CI, 92.0%–99.1%) sensitivity and 87.9% (95% CI, 81.9%–92.4%) specificity based on different thresholds applied to medial-basal and lateral temporal cortex ligand uptake (Ossenkoppele et al., 2018).

The in vivo kinetics of [18F]FTP have been investigated in a number of studies, aiming at validating semi-quantitative estimates such as the standardized uptake value ratio (SUVR), which are more appropriate for clinical research than fully dynamic and quantitative approaches (Baker et al., 2017a; Barrett et al., 2016; Golla et al., 2017; Hahn et al., 2017; Wooten et al., 2017). In those studies including blood sampling and metabolite analysis, 20–30% of [18F]FTP was found to remain 60 min after injection, with the main metabolites being polar and thus not entering the brain. Free fraction in plasma was low (0.19%) (Barret et al., 2016). The different studies came to different conclusions regarding the most appropriate kinetic model to describe ligand uptake. Whereas the two-tissue compartment model was found to best describe the data, also in the cerebellar cortex for all subjects including controls (Barret et al., 2016), others found that in controls the uptake was best described by the 1-tissue compartment model (Golla et al., 2017), indicating that model preference depended on the underlying volume of distribution. A third study found that none of the compartment models adequately described the data (Hahn et al., 2017). Most importantly, however, all studies found that reference-based quantification of dynamic data correlated well with arterial blood-based quantification supporting the use of an 80–100 (75–105) min SUVR as an acceptable, yet not ideal, method for clinical studies (see also (Heuring et al., 2018) for assessment of how regionally and temporally different times to transient equilibria influence SUVR reliability). Regional increase of ligand uptake past 180 min in certain high-binding patients might also influence semi-quantification by SUVR in earlier time frames and needs to be evaluated further. Finally, analysis of in vivo test-retest reliability of FTP yielded low variability in SUVR (standard deviation of mean percent change 1.46–3.27% depending on brain region) (Devoue Sr. et al., 2018).

3.2. Second-generation tau PET ligands

Numerous publications have applied FTP in clinical studies, as described in the next section. However, concerns about off-target binding issues (see below) have triggered the continuous development of a second generation of tau PET ligands. As data on most of these novel compounds have only been published or presented very recently, no head-to-head comparison has been conducted including any of these. Fig. 2 therefore displays current tau PET ligand uptake patterns in different representative cases of cognitively healthy elderly individuals and patients with early-onset and late-onset AD, respectively. The figure is intended to provide an impression of dynamic range and potential off-target binding patterns without claiming completeness.

After screening three final candidates (RO6958948, RO6931643, and RO6924963) (Gobbi et al., 2017), Roche decided on [18F] RO6958948 as their lead compound (Wong et al., 2018). Chemically similar to [18F]FTP (Fig. 1) and presumably binding to the T808 binding site, it is anticipated to exhibit higher affinity to mixed 3R/4R over isolated 3R or 4R tau pathology. [18F]RO6958948 was reported to have a lipophilicity of log D = 3.22 and rather low plasma free fraction of 7%. Low non-specific binding was shown using autoradiography in tissue from healthy controls, and high grey/white matter ratio in tissue samples from AD subjects with tau pathology corresponding to Braak Stage V. No significant binding was observed in vitro in PSP, CBD or PiD tissue samples (Honier et al., 2018). In a first-in-man study, 90 min dynamic scans were performed with arterial blood sampling, demonstrating clear discrimination between healthy controls and AD patients both using SUVR and volume of distribution estimates (Wong et al., 2018). For SUVR creation, a 60–90 min frame was proposed, correlating well with arterial input-based quantification. After 15 min, 30% remained as parent fraction, and the uptake could be described by a
two-tissue compartment model. No radiolabeled metabolites suspected to cross the blood-brain barrier were detected. Test-retest variability was 6–10% depending on brain region and quantification method (SUVR or DVR). [18F]RO6958948 is currently employed in a long-term study, preliminary results showed increased ligand uptake over a 1 year follow-up period (Wong et al., 2017).

Following extensive preclinical validation (Walji et al., 2016), Merck put forward [18F]MK-6240 as lead compound (Hostetler et al., 2016), demonstrating a $K_i = 0.36 \text{nM}$ in NFT-rich AD brain homogenate versus the high-affinity NFT ligand $[^3H]$NFT-355, to be compared with a $K_i = 10 \mu M$ in amyloid plaque rich AD homogenate versus the amyloid plaque ligand $[^3H]$MK-3328 (Hostetler et al., 2016). Compared with $[^3H]$FTP, $[^3H]$MK-6240 was found to have a two- to five-fold higher binding potential. Non-human primate blocking studies showed no apparent off-target binding. Three recently published studies have evaluated [18F]MK-6240 in vivo (Betthauser et al., 2018; Lohith et al., 2018; Pascoal et al., 2018). Ligand binding patterns were described in regions associated with NFT deposition. All studies included dynamic scanning for between 90 and 180 min, demonstrating rapid brain delivery and washout, and tracer kinetics were investigated in healthy controls and AD patients using reference- or blood-input based modelling approaches. Distribution volumes correlated well with SUVR over either 70–90 (Betthauser et al., 2018; Lohith et al., 2018) or 90–110 min (Pascoal et al., 2018). Whereas non-AD tauopathies have not yet been investigated with [18F]MK-6240, it presumably shares the same binding site as [18F]FTP and is thus unlikely to exhibit high

![Fig. 2. Representative PET scans using different current ligands presumably specific for tau in cognitively healthy elderly individuals (upper rows), patients with early-onset (EOAD, middle rows) and late-onset Alzheimer’s disease (LOAD, lower rows). All images were processed in a unified manner including co-registration of PET to its corresponding T1-weighted magnetic resonance imaging (MRI) scan, spatial normalization to Montreal Neurological Institute (MNI) template space and creation of standardized uptake value ratios (SUVR) using an inferior cerebellum reference region (see (Baker et al., 2017b) for methods). Note that this is not a head-to-head comparison but merely a display of sample scans from different representative cases, obtained at various sites using scanners with different spatial resolution, and non-harmonized image reconstruction. FTP images (80–100 min SUVR) were derived from the Berkeley Aging Cohort Study (BACS; University of California, Berkeley/San Francisco, Drs. William Jagust and Gil Rabinovici), [18F]GTP1 (60–90 min SUVR) images were kindly provided by Genentech (Drs. Robby Weimer and Sandra Sanabria Bohorquez), RO6958948 images (60–90 min SUVR) by Roche (Drs. Gregory Klein and Edilio Borroni) and Drs. Dean Wong and Hiroto Kuwabara from Johns Hopkins University, Baltimore, Maryland, MK6240 images (90–110 min SUVR) by Drs. Pedro Rosa-Neto and Tharick Ali Pascoal at McGill University, Montreal, Canada, and PI2620 scans (60–90 min SUVR) by Drs. André Müller and Santiago Bullich at Life Molecular Imaging GmbH (former Piramal Imaging). Aβ pos/neg: Amyloid status positive/negative based on Aβ PET scans; MMSE = Mini Mental State Examination.](image-url)
affinity to isolated 3R or 4R tau pathology.

Data for the novel \[^{18}\text{F}]\text{GTP-1} (Genentech Tau Prope-1) and \[^{18}\text{F}]\text{PI2620} (Life Molecular Imaging, formerly Piramal Imaging) compounds have thus far only been presented at conferences. \[^{18}\text{F}]\text{GTP1} is currently evaluated in a longitudinal study, preliminary cross-sectional results demonstrated clearly increased uptake in expected regions in AD patients as well as an association between ligand uptake and cognitive impairment. Images showed increased retention in the basal ganglia relative to background in some subjects but kinetic analysis suggest the measured SUVR may not necessarily reflect specific tracer binding (Sanabria Bohorquez et al., 2016; Sanabria Bohorquez et al., 2017; Weimer et al., 2017).

\[^{18}\text{F}]\text{GI2620} is structurally similar to FTP (Fig. 1), again suggesting similar binding preferences to 3R/4R tau. In \textit{in vitro} binding characteristics were reported for PHF tau deposits (IC\textsubscript{50} = 3.9 nM), K18 fibrils (4R, IC\textsubscript{50} = 8.4 nM), homogenates of AD brain (IC\textsubscript{50} = 1.9 nM), Pick’s Disease (3R, IC\textsubscript{50} = 2.6 nM), and PSP (4R, IC\textsubscript{50} = 10.7 nM), indicating high affinity to 3R/4R tau deposits but potentially also 3R inclusions (Stephens et al., 2018). No binding to \beta-amyloid or MAO-A/B was reported. \[^{18}\text{F}]\text{PI2620} is currently evaluated in several clinical trials, including a test/retest study with arterial sampling. \textit{In vivo} data showed robust brain uptake and fast wash-out in non-target regions, no lipophilic metabolites, and 20% of the intact tracer in blood at 60 min post. (Seibyl et al., 2017). SUVR over a 60–90 min post time frame were highly correlated with DVR and showed clear discrimination between AD patients and control individuals, as well as high correlation between test-retest results (Stephens et al., 2018).

4. Tau PET imaging in aging and Alzheimer’s disease

4.1. Topography of tau ligand retention

Based on years of neuropathological evidence from autopsies, the presence and location of pathological tau accumulations in the human brain are well established (Braak and Braak, 1991). These studies have proposed a progression of stages of tau deposition based on cross sectional autopsy data (see Fig. 3A). These stages begin with tau deposits in the entorhinal cortex (Braak stages I/II), moving to inferolateral temporal cortex and parts of the medial parietal lobe (stages III/IV), and eventually throughout association cortex (V/VI). Interestingly, stages III/IV can be seen in both CU older people and those with AD while stages I/II are common in those who are cognitively normal and stages V/VI are almost universally associated with dementia (Bennett et al., 2006; Hyman et al., 2012).

The relatively recent advent of relevant PET radioligands has permitted the \textit{in vivo} detection of tau which largely parallels these autopsy findings (see Fig. 3B). The radioligand \[^{18}\text{F}]\text{TFTP} has been most widely studied so far and binds with high affinity to PHF tau in AD patients (Chien et al., 2013; Lowe et al., 2016; Marquie et al., 2015). Tau tracer retention in aging and AD appears to follow a particular topography (e.g. Cho et al., 2016a) and although longitudinal data are sparse (Jack Jr. et al., 2018b; Southekal et al., 2018), the distribution can be captured as a regional pattern that appears to begin in entorhinal cortex, spreading through inferolateral temporal lobes and medial parietal lobes and eventually to wide areas of the neocortex. In contrast to \beta-A, which is often found throughout neocortex in a regionally less specific manner using PET imaging, the quantitation of tau deposition requires careful selection of region-specific measures of tracer retention. A number of different approaches have been suggested included regional and global measures for binary categorization (Jack Jr. et al., 2017; Maass et al., 2017; Mishra et al., 2017; Wang et al., 2016) as well as topographical staging approaches that recapitulate \textit{ex vivo} pattern of hierarchical tau spread (Maass et al., 2017; Schöll et al., 2016; Schwarz et al., 2016). Quantification from large regions may be sufficient to capture AD-related tau PET signal and progressive within-person accumulation of pathologic tau (Jack Jr. et al., 2018b; Maass et al., 2017). The high regionality of brain tau load as visualized with PET is further emphasized by studies employing data-driven approaches without prior definition of anatomical regions (Sepulcre et al., 2017a; Whitwell et al., 2018b).

4.2. Effects of \beta-A and age on patterns of tau PET ligand uptake

Elevated tau tracer binding in the medial temporal lobe (MTL) is commonly seen in CU elderly, whereas widespread binding in neocortical regions usually requires the presence of aggregated \beta-A (Cho et al., 2016a; Gordon et al., 2016; Johnson et al., 2016; Lockhart et al., 2017b; Maass et al., 2017; Pontecorvo et al., 2017; Schöll et al., 2016; Schwarz et al., 2016; Sepulcre et al., 2016).

Interestingly, although there is an overall correlation between the amount of \beta-A in the brain and the amount of tau (Johnson et al., 2016), the spatial locations of these two aggregated proteins are discordant. Specifically, Sepulcre and colleagues (Sepulcre et al., 2016) demonstrated strong positive local-to-local tau versus \beta-A PET correlations in lateral temporal, frontal and parietal lobes across 88 CU elderly, but tau in these regions further correlated with \beta-A throughout the brain. Data

A. Braak stages (post mortem)

Transentorhinal (I/II)

Limbic (III/IV)

Neocortical (V/VI)

B. Tau tracer uptake (PET)

Stage\textsubscript{III/IV} > Stage\textsubscript{I/II}

Stage\textsubscript{V/VI} > Stage\textsubscript{III/IV}
from Lockhart and colleagues (Lockhart et al., 2017b) con-
correlations were in medial temporal regions, speci-
A. Partial correlation (r-values) of global PiB with regional FTP PET measures in 420 cognitively normal individuals (age 50+) after adjusting for age. Highest
Fig. 4.
M. Schöll et al.
Molecular and Cellular Neuroscience 97 (2019) 18–33

meanings in 46 CU showing that tau PET signal in the temporal lobe and some frontal areas correlated with Aβ measures among widespread neocortical regions (see Fig. 4). Together these data indicate a regional vulnerability of temporal brain regions to tau regardless of where Aβ is
deposited. Notably, associations between global Aβ and regional tau
PET signal seems to be strongest in the entorhinal cortex (Vemuri et al.,
2017) as demonstrated in in large sample of 420 CU elderly, suggesting
that this “early tau region” should be included in meta regions for de-
tection of AD-related tau PET signal.

Extra-MTL tau deposition is more common in those with AD, al-
though elevated tau tracer signal in neocortical areas such as inferior
temporal or occipital cortex has been reported in those who are cog-
nitively normal and even Aβ-negative (Lowe et al.,
2018a; Lowe et al.,
2018b). While on average AD patients have more widespread and se-
vere tau deposition than controls, some AD patients who are Aβ-posi-
tive may in fact show relatively low levels of tau deposition (one pos-
sibility is that such patients are clinically misdiagnosed and have incidental Aβ-co-pathology) (Pontecorvo et al.,
2017; Wang et al.,
2016).

More Aβ deposition is not only associated with more tau deposition
in cross sectional studies, but longitudinal studies have also shown that
increasing levels of brain Aβ predict more tau deposition after several
years in limbic and neocortical Braak regions even in those who are
nominally Aβ-negative (Leal et al.,
2018; Tosun et al.,
2017). Long-
itudinal data also suggest that Aβ facilitates the spread of tau from the
MTL to the medial parietal cortex through the cingulum bundle in the
normal older brain (Jacobs et al.,
2018). Although there are still rela-
tively limited longitudinal data, it appears that longitudinal tau
accumulation is measurable in the temporal lobes in cognitively normal
individuals and those with AD, although changes have not been de-
tected in those who are Aβ-negative (Jack Jr. et al.,
2018b; Southekal et al.,
2018).

Compared to associations with Aβ, correlations between tau PET
measures and age across CU elderly seem to be weaker and be confined
to MTL regions (Maass et al.,
2018b; Schöll et al.,
2017b). Among 83 CU (Maass et al.,
2018), both Aβ and age independently predicted MTL FTP
uptake, with age only accounting for 8% of the variance compared to
25% variance explained by global Aβ. When age effects in CU adults
with normal levels of Aβ were studied across the life span (Lowe et al.,
2018b), modest age-related increases in tau PET signal were found in
most regions of the brain. Strongest differences in tau tracer binding
between young and elderly subjects are usually seen in choroid plexus
and basal ganglia, but these are thought to reflect off-target binding
(Lowe et al.,
2016; Lowe et al.,
2018b).

Age of symptom onset among AD patients clearly affects tau PET
uptake patterns. Sporadic early-onset AD patients (EOAD) exhibit dis-
tinctly greater parietotemporal and frontal ligand uptake when com-
pared to LOAD which exhibits rather confined temporal lobe uptake
(Schöll et al.,
2017a) (see also Fig. 2). Data from studies in early-onset
familial/autosomal-dominant AD are limited, suggesting earliest FTP
uptake in the MTL of Aβ-positive presymptomatic mutation carriers but
high cortical uptake, spatially comparable to sporadic EOAD cases in
later symptomatic stages ( Quiroz et al.,
2018; Schöll et al.,
2017a).

In summary, tau PET imaging data indicate that tau deposition
occurs on a continuum from normal aging through AD, likely beginning
in the entorhinal cortex within the MTL in normal aging and increasing
in both quantity and distribution with the deposition of Aβ and the

Fig. 4. Association between global Aβ and regional tau PET measures in cognitively normal elderly.
A. Partial correlation (r-values) of global PiB with regional FTP PET measures in 420 cognitively normal individuals (age 50+) after adjusting for age. Highest
B. Mean partial correlation r values for associations between global PiB DVR and FTP SUVR in different ROIs in 46 normal elderly from BACS, demonstrating strongest correlation in temporal lobe. Adapted from “Amyloid and tau PET demonstrate region-specific associations in normal older people,” (Lockhart et al., 2017b). Copyright 2017 by Elsevier.

Mean PiB-AV1451 r values

R

L

-0.55

0

0.55

24
progression towards AD with clearly different patterns in EOAD and LOAD.

4.3. Relationships between tau PET, cognition, and measures of neurodegeneration

For years, the role of Aβ in the development of AD has been perplexing because of the relatively weak association between measurements of this protein in the brain and concomitant measures of cognitive decline, whether in autopsy studies (Nelson et al., 2012), cross-sectional imaging-cognition studies (Hedden et al., 2013; Jansen et al., 2018), or longitudinal imaging studies (Donohue et al., 2017; Dubois et al., 2018). It now seems likely that this weak relationship may be explained by the intermediary factor of tau, which is correlated with both Aβ and cognition. Greater tau tracer retention is related to both poorer cognitive function cross-sectionally, and decline in cognition longitudinally although this decline has generally been measured retrospectively because of the relative novelty of tau imaging (Aschenbrenner et al., 2018; Maass et al., 2018; Schöll et al., 2016).

4.4. Findings in cognitively normal elderly

While most tau PET studies examined tau-cognition relationships in samples that included symptomatic patients with MCI or AD dementia (Aschenbrenner et al., 2018; Brier et al., 2016; Cho et al., 2016b; Johnson et al., 2016; Maass et al., 2017; Ossenkoppele et al., 2016; Schwarz et al., 2016), a few studies focused on CU elderly (Buckley et al., 2016; Maass et al., 2018; Mishra et al., 2017; Schöll et al., 2016; Shimada et al., 2017). Within CU elderly, associations are most strongly seen between episodic memory measures and tau tracer uptake in the temporal lobe (particularly entorhinal cortex, see Fig. 5), whereas associations with global cognition are either absent or found with tau PET signal in wider neocortical regions. Global Aβ does not seem to alter or account for the effect of MTL tau on episodic memory in these CU individuals (Schöll et al., 2016, Maass et al., 2018; Fig. 5A). Interestingly, similar associations have been seen between entorhinal tau load and subjective cognitive decline (Buckley et al., 2017), and these were also not altered by Aβ status. The likelihood that MTL tau accumulation is not a benign event in early stages is supported by associations between tau deposition and both brain atrophy and glucose hypometabolism in CU older people that are topographically similar to the patterns seen in patients with AD (Adams et al., 2018; Das et al., 2018; Gordon et al., 2018; Hanseeuw et al., 2017; LaPoint et al., 2017).

4.5. Findings in patients

Relationships between tau deposition, cognition, and measures of neurodegeneration are stronger yet in patients with AD. Initial studies confirmed an association between tau deposition and cognition that is stronger than the association between Aβ and cognition (Brier et al., 2016; Johnson et al., 2016). Associations with cognition are particularly striking in cases of EOAD that frequently present with dysfunction in language, visuospatial, or executive systems. In these syndromes, tau deposition bears a strong relationship to clinical phenotype, a relationship that is not seen between Aβ and clinical findings (Ossenkoppele et al., 2016; Xia et al., 2017). In AD patients, tau deposition is also associated with the neurodegenerative biomarkers of atrophy and glucose hypometabolism (Bischof et al., 2016; Iaccarino et al., 2018; Wang et al., 2016). This is also particularly marked in the syndromic variants of EOAD wherein patterns of atrophy and hypometabolism correlate better with tau than with Aβ (Ossenkoppele et al., 2016). In fact, while cognition is explained by both atrophy and tau, after accounting for atrophy tau remains correlated with cognitive function in multivariate models (Bejanin et al., 2017). EOAD has also been associated with more severe glucose hypometabolism that has not been explained by the amount or distribution of Aβ (Rabinovici et al., 2017).
4.6. Tau PET and brain connectivity

Over the last decade, the spatial correspondence between Aβ PET burden and intrinsic connectivity networks has been extensively studied, and prominent overlap with the default mode network (DMN) has been observed (Buckner et al., 2005; Grothe et al., 2016; Spierling et al., 2009). With the availability of tau PET imaging, topographical similarities between tau pathology and functional brain networks have been recently explored (Hansson, Grothe et al., 2017; Hoenig et al., 2018). In the study by Hansson and colleagues, AD-related tau PET signal primarily overlapped with the dorsal attention network and to a lower extent with higher visual, limbic and DMN network components. Hoenig et al., 2018, who identified independent coherent networks of AD-related tau PET signal, also observed a spatial correspondence of tau seed-based functional networks with multiple resting-state networks. In their data, spatial similarities were highest with ventral and dorsal DMN but also evident with salience, language, primary and higher visual, as well as hippocampal networks. Together these findings indicate that tau pathology does not exclusively distribute along one particular network.

Other studies characterized the spatial associations of tau and Aβ PET load with functional connectivity changes in the brains of CU elderly (Schultz et al., 2017; Sepulcre et al., 2017b) and AD dementia patients (Cope et al., 2018; Jones et al., 2017; Wiertpert et al., 2017). Among older adults, an inverse relationship of tau versus Aβ PET measures with functional connectivity hubs was observed such that tau tended to be located in areas of hypoconnectivity (e.g. temporal lobe) but Aβ in areas of hyperconnectivity (e.g. occipital and parietal lobe) (Sepulcre et al., 2017b). Schultz and colleagues (Schultz et al., 2017) furthermore showed an interactive effect of global Aβ and neocortical tau PET measures on functional connectivity. While hyperconnectivity in DMN and salience networks was seen in OA with high Aβ but low levels of inferior temporal tau, hypoconnectivity was present when both global Aβ and neocortical tau were high. These cross-sectional findings could be interpreted as support for a phase of hyperconnectivity in Aβ-positive aging, followed by a loss of connectivity with spread of tau to neocortical regions in the progression of AD.

The cascading network failure model proposed by Jones and colleagues (Jones et al., 2016) incorporated findings about the relationship between tau, Aβ and functional network changes (Jones et al., 2017; Wiertpert et al., 2017). The model suggests that local tau-associated network disruptions (e.g. in temporal lobe) lead to compensatory load shift to the posterior DMN and subsequently other connectivity hubs (evident as increased connectivity) that are associated with amyloidosis and network failure. Longitudinal data across the AD spectrum will be necessary to elucidate the sequential order of tau and Aβ accumulation and associated functional network changes.

5. Off-target binding of tau PET ligands

Off-target binding of tau PET ligands is one of the current major limitations and challenges to be addressed in novel tracer development (see also (Bischof et al., 2017, Lemoine et al., 2018, Lois et al., 2018) for recent reviews).

5.1. Flortaucipir (FTP)

Among tracers, FTP off-target binding has been characterized best and has been most frequently reported in the basal ganglia, substantia nigra, choroid plexus, meninges and vessels (see also Fig. 2).

5.1.1. Basal ganglia and substantia nigra

The strong FTP uptake in caudate, putamen, and pallidum seen in elderly individuals regardless of their clinical diagnosis (e.g. (Baker et al., 2017b; Brier et al., 2016, Lowe et al., 2016, Vemuri et al., 2017, Winer et al., 2018)) has been attributed to iron binding. In groups of patients and controls, basal ganglia FTP signal correlated with age-related increases in iron accumulation measured by iron-sensitive R2+ MRI (Choi et al., 2018).

Similarly, FTP binds strongly to substantia nigra, also in cases with no tau pathology, which has been related to neuromelanin (Marquie et al., 2015; Marquie et al., 2017b; Marquie et al., 2017c). This is in accordance with reduced substantia nigra FTP signal seen in PD patients without (Hansen et al., 2016) or with (Smith et al., 2018) dementia compared to age-matched controls, that might reflect decreases in neuromelanin containing dopaminergic neurons (but see Winer et al., 2018 for different findings). Other neuromelanin and melanin containing structures that show elevated FTP binding include pituitary, retinal pigment epithelial cells, leptomeninges, and malignant melanocytes in metastatic melanoma (Lowe et al., 2016; Marquie et al., 2015; Marquie et al., 2017b).

5.1.2. Choroid plexus

High FTP signal in choroid plexus is commonly seen in older individuals and interferes with quantification of hippocampal uptake due to the close proximity of both structures. In choroid plexus, FTP signal has been shown to co-localize with calcification/mineralization (Lowe et al., 2016). Histology data has further suggested that there might be “on-target” binding in the choroid plexus to tangle-like structures corresponding to Bioni “ring” tangles (Ikonomovic et al., 2004). Moreover, melanocyte FTP binding might partially account for high choroid plexus signal (Marquie et al., 2015; Marquie et al., 2017c) as proposed by race differences seen between Black/African American and white participants from the Harvard Aging Brain Study (HABS) (Lee et al., 2018).

PVC approaches that include choroid plexus (Baker et al., 2017b; Wolters et al., 2018) as region of interest can help to reduce spill-in effects of choroid plexus signal to hippocampal signal (Lee et al., 2018; Maass et al., 2017; Maass et al., 2018; Schöll et al., 2016).

5.1.3. MAO

In vitro data (Vermeiren et al., 2018) showed that FTP binds to MAO-A and B at a similarly high affinity as it binds to tau fibrils in brain homogenates. MAO-B is a protein highly expressed in all brain regions and increases with age (e.g. Fowler et al., 1997). Hansen and colleagues (Hansen et al., 2018), however, did not observe significant differences
in vivo between FTP scans of non-demented PD patients with and without MAO-B inhibitors, suggesting that FTP does not bind significantly to MAO-B in vivo.

Increased FTP signal is further seen in blood vessels, hemorrhages and infarcts, and suggests binding to blood components (Lockhart et al., 2017a; Lowe et al., 2016; Marquie et al., 2015).

5.2. Other tau PET ligands

Similar off-target binding profiles as seen for FTP have been described for [11C]PB83 and [18F]THK compounds with off-target binding in choroid plexus, basal ganglia, substantia nigra and meninges (Bethehauer et al., 2017b; Chiotsi et al., 2018; Lemoine et al., 2017).

For [18F]THK5351, strong binding to MAO-B has been demonstrated in vivo and ex vivo (Harada et al., 2018; Ng et al., 2017b). In particular, application of the MAO-B inhibitor seleagine in eight patients reduced regional SUVs by > 50% in the thalamus and basal ganglia, and > 40% in cerebellar cortex, preventing accurate quantification of tau levels by means of this tracer (Ng et al., 2017b).

Second-generation tau tracers (see above) seem to be hampered less by off-target binding (see also Fig. 2), however, most of these results have to be replicated in larger samples in vivo. For instance, preclinical evaluation of three novel Roche compounds ([11C]RO6958948, [11C]RO6931643 and [11C]RO6929463) suggests lack of any significant off-target binding in vivo demonstrated by autoradiography and displacement studies (Honert et al., 2018). In vivo imaging with [18F]MK6240 in a sample of patients and OA revealed off-target binding to ethmoid sinus, clivus, meninges, substantia nigra, but not the basal ganglia or choroid plexus (Bethehauer et al., 2018; Pascoal et al., 2018). Although the lack of off-target binding to choroid plexus is a major advance allowing quantification of hippocampal signal, ethmoid sinus uptake that spills into the orbitofrontal cortex and meningeal uptake affecting various cortical regions does still limit quantification in these areas (see Fig. 2). Delfurinolization of MK-6240 yields a low bone signal (Lohith-fluorination of MK-6240 yields a low bone signal (Lohith et al., 2018) at late scanning time points that does likely not affect the quantification of cortical signal. It has been speculated that tracer accumulation around the skull might derive from a non-brain penetrating circulating metabolite. Considering extracortical hotspots in PVC approaches might thus be useful for all current tau PET tracers (Baker et al., 2017b).

6. Tau PET findings in other tauopathies

Autoradiography studies in post mortem tissue have so far found only weak to moderate binding of existing tau PET ligands to pure 3R- or 4R target binding in choroid plexus, basal ganglia, substantia nigra and meninges (Bethehauer et al., 2017b; Chiotsi et al., 2018; Lemoine et al., 2017).

For [18F]THK5351, strong binding to MAO-B has been demonstrated in vivo and ex vivo (Harada et al., 2018; Ng et al., 2017b). In particular, application of the MAO-B inhibitor seleagine in eight patients reduced regional SUVs by > 50% in the thalamus and basal ganglia, and > 40% in cerebellar cortex, preventing accurate quantification of tau levels by means of this tracer (Ng et al., 2017b).

Second-generation tau tracers (see above) seem to be hampered less by off-target binding (see also Fig. 2), however, most of these results have to be replicated in larger samples in vivo. For instance, preclinical evaluation of three novel Roche compounds ([11C]RO6958948, [11C]RO6931643 and [11C]RO6929463) suggests lack of any significant off-target binding in vivo demonstrated by autoradiography and displacement studies (Honert et al., 2018). In vivo imaging with [18F]MK6240 in a sample of patients and OA revealed off-target binding to ethmoid sinus, clivus, meninges, substantia nigra, but not the basal ganglia or choroid plexus (Bethehauer et al., 2018; Pascoal et al., 2018). Although the lack of off-target binding to choroid plexus is a major advance allowing quantification of hippocampal signal, ethmoid sinus uptake that spills into the orbitofrontal cortex and meningeal uptake affecting various cortical regions does still limit quantification in these areas (see Fig. 2). Delfurinolization of MK-6240 yields a low bone signal (Lohith et al., 2018) at late scanning time points that does likely not affect the quantification of cortical signal. It has been speculated that tracer accumulation around the skull might derive from a non-brain penetrating circulating metabolite. Considering extracortical hotspots in PVC approaches might thus be useful for all current tau PET tracers (Baker et al., 2017b).

In vivo data from CBS (corticobasal syndrome) patients proposed that FTP PET might be useful for distinguishing e.g. CBD pathology from AD or PSP (Josephs et al., 2016; Smith et al., 2017c). Weakly increased uptake was demonstrated in subcortical structures, the motor cortex in the hemisphere contralateral brain to the most affected body side, and white matter tracts corresponding to the cortico-spinal tract (Smith et al., 2017c). However, grey matter atrophy was more pronounced and not associated with FTP uptake in these patients.

Finally, slightly elevated cortical tau PET uptake has been observed in Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) (Smith et al., 2018) while substantia nigra signal was decreased in Parkinson’s disease (PD) (Cho et al., 2017; Coakeley et al., 2018; Smith et al., 2018). In PDD patients, cognitive impairment was correlated with increased tau burden. Another study reported no difference in cortical FTP uptake between CU elderly, patients with PD-MCI and PD without cognitive impairment (Winer et al., 2018).

Further in vitro and in vivo studies are needed, especially for second-generation tau ligands, to inform the use of tau PET in non-AD neurodegenerative disorders.

7. Concordance between imaging and fluid biomarkers for tau

To our knowledge, only six studies have simultaneously tested CSF tau biomarkers and tau PET imaging (using data from four different cohorts). Some studies have largely focused on CU individuals (Brier et al., 2016; Chhatwal et al., 2016; Gordon et al., 2016), while others have focused more on symptomatic stages of AD (La Joie et al., 2018; Mattsson et al., 2017b; Mattsson et al., 2018b), or other neurodegenerative diseases (La Joie et al., 2018). All these studies used FTP PET. Chhatwal et al. (Chhatwal et al., 2016) tested 31 CU persons from HABS, with CSF biomarkers analyzed by the Aβ2/40/42 assays, and FTP quantified in predefined ROIs. Correlations between CSF biomarkers and FTP were strongest for CSF P-tau, and were significant in total cortex, several temporal ROIs and a parietal ROI (the strongest correlation was seen in inferior temporal cortex). Both CSF T-tau and P-tau were significantly correlated with FTP in entorhinal, parahippocampal, middle temporal, and inferior temporal cortex. Brier et al. (Brier et al., 2016) tested 31 CU and 5 impaired persons (two CDR 0.5 and three CDR > 0.5) from a St Louis cohort, with CSF biomarkers analyzed by INNOTEST assays. The mean grey matter FTP correlated with greater CSF T-tau (but not significantly with P-tau). Brier et al. used an elastic net procedure to define regional PET “topographies”. The strongest contributions to prediction of CSF T-tau came from cuneus, entorhinal cortex, transverse temporal sulcus, and (with a negative coefficient) hippocampus. The authors found similar topographies for P-tau. In another study from the St Louis cohort, Gordon et al. (Gordon et al., 2016), studied 41 CU (15 of these were Aβ+ defined by [11C]Pib or [18F]FDDPF PET imaging) and 11 impaired persons (seven CDR 0.5, four CDR > 0.5; 10 of these were Aβ+). In the entire cohort, there were significant relationships for all CSF biomarkers and FTP, but when the correlations were restricted to CU, CSF T-tau and P-tau were no longer associated with FTP (but reduced CSF Aβ42 was associated with greater FTP in both the whole cohort and in CU).

In the Swedish BioFINDER cohort, Mattsson et al. tested 30 CU (15 of these were Aβ+ defined by CSF Aβ42), 14 prodromal AD (Aβ+ MCI) and 39 AD dementia (all Aβ+)+ patients, with CSF biomarkers analyzed by INNOTEST assays. CSF T-tau and P-tau were moderately associated with retention of FTP, and associations were mainly seen in the dementia group (Mattsson et al., 2017b), voxelwise analyses (adjusted for diagnostic group) showed widespread associations in frontal, temporal and parietal regions between the CSF biomarkers and FTP, with more prominent associations for T-tau than P-tau. CSF tau biomarkers were increased in preclinical AD, while FTP was more strongly increased in symptomatic stages of the disease. In line with this, FTP but not CSF T-tau or P-tau, was strongly associated with atrophy and results on cognitive tests, (even when adjusting for diagnostic group). When using dichotomous classifications, regional FTP and CSF tau measures were most often concordant, especially in...
dementia patients. Another paper on the same cohort presented diagnostic accuracies for the different biomarkers (Mattsson et al., 2018b). The diagnostic accuracies for prodromal AD versus CU were similar for CSF tau biomarkers (both T-tau, AUC 0.86; and P-tau, AUC 0.94) and FTP (using a temporal lobe composite, AUC 0.92), while FTP had superior accuracy for AD dementia versus CU (AUC 1.00; T-tau, AUC 0.88; P-tau, AUC 0.89).

In a study on a UCSF cohort, La Joie et al. (La Joie et al., 2018) tested 28 AD patients (3 with prodromal AD and 25 with AD dementia) and 25 non-AD neurodegenerative patients. CSF biomarkers were analyzed by AlzBio3. Cortical FTP and P-tau both had excellent discrimination for Aβ-positive AD versus non-AD conditions (AUC 0.92–0.94), with high classification agreement (83%). When restricted to Aβ-positive patients with AD, FTP correlated modestly with both P-tau and T-tau. Regionally, FTP correlated with CSF P-tau in temporoparietal cortices and with T-tau in medial prefrontal regions. Within AD, MMSE scores were associated with FTP, but not CSF biomarkers.

In summary, these six studies found that CSF tau measures were moderately correlated with FTP, with strongest correlations in symptomatic stages of AD, and weaker or non-significant correlations in CU. CSF T-tau and P-tau were similarly correlated to FTP in CU and AD (Brier et al., 2016; Chhatwal et al., 2016; Gordon et al., 2016; Mattsson et al., 2017b; Mattsson et al., 2018b), but when non-AD neurodegenerative patients were included, P-tau rather than T-tau provided more FTP-like information (La Joie et al., 2018). This suggests that in non-AD conditions, these CSF biomarkers may be differentially regulated, perhaps because T-tau (but not P-tau) secretion is increased in a non-disease specific fashion due to neuronal injury. Another common finding was that cognitive measures (La Joie et al., 2018; Mattsson et al., 2017b) and atrophy (Mattsson et al., 2017b) were related to FTP but not to CSF tau measures (when adjusting for clinical diagnosis of AD, otherwise CSF tau measures are strongly correlated to both atrophy and cognition, as shown many times before). One possible interpretation is that CSF tau biomarkers reach a plateau during the prodromal stage of the disease, when the FTP uptake still continues to increase. One study (Mattsson et al., 2017b) suggested that changes in CSF tau measures may be detectable before changes in the FTP signal. Notably, the overall results were quite similar between the different studies, despite the use of different methods for FTP quantification, different CSF assays and different statistical procedures.

The different dynamics of imaging and fluid markers of tau pathology at different stages of AD may have implications for their use in clinical trials and practice. Taken together, the results suggest that CSF tau biomarkers have properties that make them suitable for the identification of “disease state”, i.e. the presence of a pathological process associated with AD. Their relative lack of dynamic changes later during the disease and their poor correlation with measures of cognition and atrophy at the symptomatic stages of AD make them less suitable as markers of “disease stage”. In contrast, tau PET imaging may lack sensitivity very early in the disease, but the continuous accumulation of signal, and the strong correlations with cognition and atrophy make tau PET imaging a powerful marker of “disease stage” in AD.

8. Conclusions and future perspectives

The availability of techniques to measure and map Aβ transformed clinical and translational research on aging and dementia many years ago. Now, within the past several years, methods of measuring tau pathology in the brain, following the earlier development of tau measures in CSF, have furthered this transformation. The clearest example of this is the proposal of a new framework for biomarker applications in which the conjoint presence of Aβ and tau pathology, regardless of the presence or nature of symptoms, establishes an individual as having AD (Jack Jr. et al., 2018a). While this approach is not proposed for clinical use, the research definition of AD as a biological entity, as opposed to a clinical syndrome, will further mechanistic studies and therapeutic developments. These advances in both methods and concepts have of course not yet lead to an effective treatment for AD. However, the availability of both Aβ and tau biomarkers derived from both bodily fluid analyses and brain imaging is changing the landscape of human AD research.

Measurement of tau in CSF and brain are relatively recent developments, and longitudinal data, especially for tau PET, are only just being acquired. Longitudinal studies of both Aβ and tau biomarkers, paired with measurements of neurodegeneration and cognition, will be necessary to establish temporal relationships between molecular events. These studies will take time to accrue the necessary samples, but should pay off in important scientific knowledge. Some of the most basic questions in the field involve the relationships between Aβ and tau, and how or whether one protein leads to aggregation of the other. Similarly, the time course of aggregation, spread, and pathological effects needs to be elucidated. Large, longitudinal cohort studies using multiple biomarkers will be crucial in answering these basic questions.

Use of biomarkers in the development of therapeutic trials is also important and growing. We have already witnessed new approaches based on measurement of Aβ; clinical trials using Aβ-lowering therapies now require measurement of Aβ for enrollment and usually measure treatment effects on biomarkers to track target engagement. Tau measurements are sure to serve similar roles in the development of anti-tau therapeutics. Furthermore, tau may be useful in providing a measure of disease progression even for therapeutic approaches that do not target tau directly. That is, therapies may be targeted to a “sweet spot” such that symptoms are at a stage where amelioration is possible, but treatment is not yet futile. Tau measurements may help to identify this timing.

There are indeed many major technical and methodological challenges yet to overcome. For PET, while Aβ imaging agents seem to be largely comparable and methods for their quantitative comparison have been proposed (i.e., the CENTILOID approach (Klunk et al., 2015)), it is not clear that this is the case for tau ligands. Some tau ligands have not yet seen wide application, and methods for quantitation even for a single tracer are not uniformly established. Comparability across methods and tracers will require attention, as will the assessment of comparability between fluid- and imaging-derived biomarkers.

Finally, it is increasingly recognized that Aβ and tau biomarkers, while the most ubiquitously expressed pathologically aggregated proteins, are not the only ones involved in neurodegenerative diseases. Methods for measurement of alpha-synuclein and TDP-43 will likely be important in establishing an even more complete picture of the brain in aging and dementia.

Acknowledgements

The authors gratefully acknowledge all patients and their relatives who have made the studies described here possible as well as all research groups whose work has contributed to this field. We also thank Dr. Kerstin Heurling for providing expert input. MS has received funding from the Knut and Alice Wallenberg Foundation (Wallenberg Centre for Molecular and Translational Medicine), the Swedish Research Council, the Swedish Alzheimer Foundation, the Swedish State under the agreement between the Swedish Government and the county councils (ALF), and the Sahlgrenska Academy; NM has received funding from the Swedish Research Council, The Brain Foundation, and The Swedish Medical Association. AM has received funding from the Helmholtz Association; HZ is a Wallenberg Academy Fellow and is additionally funded by grants from the Swedish Research Council and the European Research Council; KB holds the Torsten Söderberg Professorship in Medicine, and is supported by grants from the Swedish Alzheimer Foundation, the Swedish Brain Foundation, and the Swedish Research Council.
Olsson, B., Lauter, N., Andreason, U., Ohrfelt, A., Portelius, E., Bjerke, M., Holm, M., Rosen, C., Olsson, C., Str€obel, G., Wu, E., Dakin, K., Petzold, M., Blennow, K., Zetterberg, H., 2016. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurology 15, 673–684.

Oro, M., Shima, S., Shimada, H., Sahra, N., Takowa, H., Yoshii, Y., Tzvetanov, J.Q., Lee, V., Suhara, T., Zhang, M.-R., Jang, M.K., Tamagnan, G., Marek, K., Higuchi, M., 2017a. Distinct variation of tau PET tracers in neurons of Alzheimer's disease vs other neurodegenerative disorders. JAMA Network Open 10, 1151–1162.

Ossenkoppele, R., Schonhaut, D.R., Schöll, M., Alagille, D., Jogi, J., Kruppa, D., Dickson, D.W., Tzvetanov, J.Q., Lee, V.-M., Yohida, M., Hozumi, I., Yoshii, Y., van Swieten, J.C., Nordberg, A., Suhara, T., Zhang, M.-R., Higuchi, M., 2017b. Distinct binding of PET ligands PB33 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain 140, 746–780.

Ossenkoppele, R., Rabinovici, G., Smith, R., Cho, H., Scholl, M., Strandberg, Ø., Palmqvist, S., Mattsson, N., Janedal, S., Santillo, A., Olsson, T., Jogi, J., Tsai, S., Los Angeles, R., Kramer, J., Boe, A., Gorme-Tempini, M., Choi, J., Ryu, Y., Lyoo, G., et al., 2018. Identification of altered tau protein expression in late-onset Alzheimer's disease vs other neurodegenerative disorders. JAMA Network Open 20, 10, 111–1126.

Ossenkoppele, R., Schonhaut, D.R., Schöll, M., Schöll, M., Stroj, M., Hoft, E., Ayalon, G., Rubenstein, R., Yue, J.K., Chiu, A., Winkler, E.A., Puccio, A.M., Diaz-Arrastia, Ren, R.J., Dammer, E.B., Wang, G., Seyfried, N.T., Levey, A.I., 2014. Proteomics of prodromal Alzheimer disease vs other neurodegenerative disorders. JAMA Network Open 30, (11), 1151–1162.

Ossenkoppele, R., Schonhaut, D.R., Schöll, M., Alagille, D., Jogi, J., Kruppa, D., Dickson, D.W., Tzvetanov, J.Q., Lee, V.-M., Yoshida, M., Hozumi, I., Yoshii, Y., Van Swieten, J.C., Nordberg, A., Suhara, T., Zhang, M.-R., Higuchi, M., 2017a. Distinct binding of PET ligands PB33 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain 140, 746–780.

Ossenkoppele, R., Schonhaut, D.R., Schöll, M., Alagille, D., Jogi, J., Kruppa, D., Dickson, D.W., Tzvetanov, J.Q., Lee, V.-M., Yoshida, M., Hozumi, I., Yoshii, Y., Van Swieten, J.C., Nordberg, A., Suhara, T., Zhang, M.-R., Higuchi, M., 2017. Distinct binding of PET ligands PB33 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain 140, 746–780.

Ossenkoppele, R., Schonhaut, D.R., Schöll, M., Alagille, D., Jogi, J., Kruppa, D., Dickson, D.W., Tzvetanov, J.Q., Lee, V.-M., Yoshida, M., Hozumi, I., Yoshii, Y., Van Swieten, J.C., Nordberg, A., Suhara, T., Zhang, M.-R., Higuchi, M., 2017b. Distinct binding of PET ligands PB33 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain 140, 746–780.

Ossenkoppele, R., Schonhaut, D.R., Schöll, M., Alagille, D., Jogi, J., Kruppa, D., Dickson, D.W., Tzvetanov, J.Q., Lee, V.-M., Yoshida, M., Hozumi, I., Yoshii, Y., Van Swieten, J.C., Nordberg, A., Suhara, T., Zhang, M.-R., Higuchi, M., 2017a. Distinct binding of PET ligands PB33 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain 140, 746–780.

Ossenkoppele, R., Schonhaut, D.R., Schöll, M., Alagille, D., Jogi, J., Kruppa, D., Dickson, D.W., Tzvetanov, J.Q., Lee, V.-M., Yoshida, M., Hozumi, I., Yoshii, Y., Van Swieten, J.C., Nordberg, A., Suhara, T., Zhang, M.-R., Higuchi, M., 2017b. Distinct binding of PET ligands PB33 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain 140, 746–780.

Ossenkoppele, R., Schonhaut, D.R., Schöll, M., Alagille, D., Jogi, J., Kruppa, D., Dickson, D.W., Tzvetanov, J.Q., Lee, V.-M., Yoshida, M., Hozumi, I., Yoshii, Y., Van Swieten, J.C., Nordberg, A., Suhara, T., Zhang, M.-R., Higuchi, M., 2017a. Distinct binding of PET ligands PB33 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain 140, 746–780.
Pirttilä, T. 2009. Cerebrospinal fluid (beta)-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 66, 382–389.

Tatebe, H., Kasai, T., Ohmichi, T., Kish, Y., Kakuya, T., Waragai, M., Kondo, M., Allopp, D., Tokuda, T. 2017. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome. Mol. Neurodegener. 12, 63.

Tosun, D., Landau, S., Aisen, P.S., Petersen, R.C., Mintun, M., Jagust, W., Weiner, M.W., Alzheimer’s Disease Neuroimaging. L. 2017. Association between tau deposition and antecedent amyloid-beta accumulation rates in normal and early symptomatic individuals. Brain 140, 1499–1512.

Tzen, K.V., Yang, S.Y., Chen, T.F., Cheng, T.W., Hong, H.E., Wen, H.P., Huang, Y.Y., Shiue, C.Y., Chiu, M.J., 2014. Plasma Abeta but not tau is related to brain filling in early Alzheimer’s disease. ACS Chem. Neurosci. 5, 830–836.

Vemuri, P., Lowe, V.J., Knopman, D.S., Senjem, M.L., Kemp, B.J., Schwartz, C.G., Przybelski, S.A., Machulda, M.M., Petersen, R.C., Jack Jr., C.R., 2017. Tau PET up- take: regional variation in average SUVR and impact of amyloid deposition. Alzheimers Dement. (Amst) 6, 21–30.

Vemuri, P., Knopman, D.S., Lowe, V.J., Lipton, B., Knudtson, M., Petersen, R.C., Jack Jr., C.R., 2018. Evaluation of tau [18F]GTP1 (Genentech Tau Probe 1) PET imaging. In: Human Amyloid Imaging Meeting, pp. 70.

Walji, A.M., Hostetler, E.D., Selnick, H., Zeng, Z., Miller, P., Bennacef, I., Salinas, C., Vermeiren, C., Motte, P., Viot, D., Citron, M., Mercier, J., Masliah, E., Rissman, R.A., 2016. Prediction of conversion from mild cognitive impairment to dementia with brain amyloid beta protein pathophysiology. In: Human Amyloid Imaging Meeting, pp. 70.